Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1Phase 2 1

Status

Completed 119Unknown 65Recruiting 26Terminated 24Active not recruiting 17Not yet recruiting 11Withdrawn 3Suspended 1

Sponsor Class

OTHER 3INDUSTRY 2OTHER_GOV 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 2Gastrointestinal 1

Conditions

Breast Neoplasms 2Carcinoma, Hepatocellular 1

Interventions

Radiotherapy 91pembrolizumab 88Cyclophosphamide 84Gemcitabine 70Cisplatin 70Magnetic Resonance Spectroscopy 65Carboplatin 60Radiosurgery 55Paclitaxel 55Nivolumab 48Dexamethasone 45Bevacizumab 42Biopsy 41Fluorouracil 39durvalumab 37Surveys and Questionnaires 36Docetaxel 36fludarabine 35Doxorubicin 35Radiation 33Oxaliplatin 33Capecitabine 33Rituximab 32fludarabine phosphate 31Leucovorin 31Cytarabine 30Melphalan 29Etoposide 28Pemetrexed 27Irinotecan 27

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Withdrawn × OTHER × Epirubicin × Clear all
NCT02067416 2023-02-02

PREDATOR: Neoadjuvant Gene Prediction for Breast Cancer

The Methodist Hospital Research Institute

Phase 2 Withdrawn
Breast

Breast Neoplasms

NCT01159236 2012-07-31

Molecular Triaging of Newly Diagnosed Breast Cancer

M.D. Anderson Cancer Center

Phase NA Withdrawn
Breast

Breast Neoplasms

NCT01327521 2012-06-11

Transarterial Chemoembolization vs CyberKnife for Recurrent Hepatocellular Carcinoma

Stanford University

Phase 3 Withdrawn
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡